Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avenciguat alone or with empagliflozin for portal hypertension in compensated cirrhosis
jRCT2031220376Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2022
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of avenciguat and empagliflozin in Portal Hypertension (PH) and Cirrhosis (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage change in hepatic venous pressure gradient from baseline after 8 weeks. Started Oct 2022; status: completed.
02
Drugs
avenciguatempagliflozin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on jRCT2031220376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220376.